Please login to the form below

Not currently logged in
Email:
Password:

Apitope strengthens its board with new director

Dr William Jenkins joins the board following a 30-year career in clinical medicine

Dr William JenkinsClinical stage biotech Apitope has appointed Dr William Jenkins as its independent, non-executive director to its board.

Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and research.

He has also served on several boards including Ablynx, Evotec and Acambis.

Stéphane Verdood, chairman of the board, said: “We are pleased to welcome William to Apitope’s board of directors.

“William’s extensive drug development expertise is a valuable addition as we seek to advance development of our potential first-in-class antigen-specific treatments targeted at autoimmune diseases.

“William has advised companies through various stages of growth to maturity and I know he will provide further strength and depth to the board.”

22nd March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics